WO2005048952A3 - Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle - Google Patents
Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle Download PDFInfo
- Publication number
- WO2005048952A3 WO2005048952A3 PCT/US2004/038409 US2004038409W WO2005048952A3 WO 2005048952 A3 WO2005048952 A3 WO 2005048952A3 US 2004038409 W US2004038409 W US 2004038409W WO 2005048952 A3 WO2005048952 A3 WO 2005048952A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- composition
- amphiphilic molecule
- suspension vehicle
- delivery system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006541326A JP4824574B2 (en) | 2003-11-17 | 2004-11-16 | Compositions and dosage forms comprising amphiphilic molecules as suspension vehicles |
MXPA06005565A MXPA06005565A (en) | 2003-11-17 | 2004-11-16 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle. |
NZ547079A NZ547079A (en) | 2003-11-17 | 2004-11-16 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
BRPI0416613-2A BRPI0416613A (en) | 2003-11-17 | 2004-11-16 | composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
CA002546321A CA2546321A1 (en) | 2003-11-17 | 2004-11-16 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
EP04811199A EP1689363A4 (en) | 2003-11-17 | 2004-11-16 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
AU2004291162A AU2004291162B2 (en) | 2003-11-17 | 2004-11-16 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
IL175606A IL175606A (en) | 2003-11-17 | 2006-05-11 | Pharmaceutical compositions comprising a suspending vehicle and a particle preparation and an osmotic drug delivery device thereof |
NO20062867A NO20062867L (en) | 2003-11-17 | 2006-06-19 | Compound and dosage form comprising an amphiphilic molecule as suspension vehicle |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52060503P | 2003-11-17 | 2003-11-17 | |
US60/520,605 | 2003-11-17 | ||
US10/988,716 | 2004-11-15 | ||
US10/988,716 US7731947B2 (en) | 2003-11-17 | 2004-11-15 | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005048952A2 WO2005048952A2 (en) | 2005-06-02 |
WO2005048952A3 true WO2005048952A3 (en) | 2005-12-29 |
Family
ID=34594998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/038409 WO2005048952A2 (en) | 2003-11-17 | 2004-11-16 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
Country Status (15)
Country | Link |
---|---|
US (6) | US7731947B2 (en) |
EP (2) | EP1689363A4 (en) |
JP (1) | JP4824574B2 (en) |
KR (1) | KR20060123160A (en) |
AR (1) | AR046844A1 (en) |
AU (1) | AU2004291162B2 (en) |
BR (1) | BRPI0416613A (en) |
CA (1) | CA2546321A1 (en) |
IL (1) | IL175606A (en) |
MX (1) | MXPA06005565A (en) |
NO (1) | NO20062867L (en) |
NZ (1) | NZ547079A (en) |
PE (1) | PE20050926A1 (en) |
TW (1) | TW200534863A (en) |
WO (1) | WO2005048952A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940316B2 (en) | 2005-02-03 | 2015-01-27 | Intarcia Therapeutics, Inc. | Osmotic delivery comprising an insulinotropic peptide and uses thereof |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
JP2005533782A (en) * | 2002-06-17 | 2005-11-10 | アルザ コーポレイション | An osmotic delivery system having an engine with fast extruding force and zero order including an osmotic agent dispersed in a fluid vehicle |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
KR20050120767A (en) * | 2003-03-31 | 2005-12-23 | 알자 코포레이션 | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
AR043809A1 (en) * | 2003-03-31 | 2005-08-17 | Alza Corp | OSMOTIC PUMP WITH MEDIUM TO DISSIP INTERNAL PRESSURE |
ES2737835T3 (en) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Hydraulically driven pump for long-term medication administration |
ATE554664T1 (en) * | 2003-09-09 | 2012-05-15 | 3M Innovative Properties Co | CONCENTRATED ANTIMICROBIAL COMPOSITIONS AND METHODS |
CN1867251A (en) * | 2003-09-09 | 2006-11-22 | 3M创新有限公司 | Antimicrobial compositions and methods |
US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US7407499B2 (en) * | 2003-10-31 | 2008-08-05 | Intarcia Therapeutics, Inc. | Osmotic pump with self-retaining, fast-start membrane plug |
MXPA06003065A (en) * | 2003-11-06 | 2006-05-31 | Alza Corp | Modular imbibition rate reducer for use with implantable osmotic pump. |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20060045891A1 (en) * | 2004-08-24 | 2006-03-02 | Lovalenti Phillip M | Density-matched suspension vehicles and pharmaceutical suspensions |
US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
EP2206495B1 (en) | 2005-01-14 | 2012-11-21 | Camurus AB | Topical bioadhesive formulations |
ATE501710T1 (en) | 2005-01-14 | 2011-04-15 | Camurus Ab | SOMATOSTATIN ANALOG FORMULATIONS |
JP5127466B2 (en) | 2005-01-21 | 2013-01-23 | カムルス エービー | Pharmaceutical lipid composition |
US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006084141A2 (en) * | 2005-02-03 | 2006-08-10 | Intarcia Therapeutics, Inc | Suspension formulation of interferon |
US20060229364A1 (en) * | 2005-03-10 | 2006-10-12 | 3M Innovative Properties Company | Antiviral compositions and methods of use |
EP1868686A2 (en) * | 2005-03-10 | 2007-12-26 | 3M Innovative Properties Company | Antimicrobial pet wipes |
US8476319B2 (en) * | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
CA2599667C (en) * | 2005-03-10 | 2014-12-16 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxy carboxylic acids |
KR20070113284A (en) | 2005-03-10 | 2007-11-28 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | Methods of reducing microbial contamination |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
CN101217940B (en) | 2005-06-06 | 2013-03-27 | 卡穆鲁斯公司 | Glp-1 analogue formulations |
AR055099A1 (en) * | 2005-07-28 | 2007-08-08 | Alza Corp | LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES |
EP2241327A1 (en) * | 2006-03-15 | 2010-10-20 | Novo Nordisk A/S | Mixtures of Amylin and Insulin |
DE102006013531A1 (en) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Drug delivery system, useful for supplying active substance to central nervous system of a mammal over the blood-brain barrier, comprises: nanoparticles of poly(DL-lactide-co-glycolide) and pharmaceutical substance e.g. cytostatic agent |
JP2009532117A (en) | 2006-03-30 | 2009-09-10 | ヴァレリタス,エルエルシー | Multi-cartridge fluid dispensing device |
KR101200728B1 (en) * | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
US20080075793A1 (en) * | 2006-09-21 | 2008-03-27 | Dunshee Wayne K | Antiviral compositions and methods of use |
CN101687044B (en) * | 2007-05-25 | 2014-10-29 | 不列颠哥伦比亚大学 | Formulations for the oral administration of therapeutic agents and related methods |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
PT2020221E (en) * | 2007-06-19 | 2012-05-30 | Neubourg Skin Care Gmbh & Co Kg | Dms (derma membrane structure) in foaming creams |
GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
KR100970911B1 (en) * | 2007-12-13 | 2010-07-20 | 재단법인서울대학교산학협력재단 | External preparation comprising triazole derivative antifungal agent and preparation method thereof |
WO2009092040A2 (en) * | 2008-01-17 | 2009-07-23 | Gary Dean Bennett | Topical pain formulation |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
EP2161019A1 (en) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
KR101419583B1 (en) * | 2008-10-15 | 2014-07-25 | 인타르시아 세라퓨틱스 인코포레이티드 | Highly concentrated drug particles, formulations, suspensions and uses thereof |
WO2011005311A1 (en) * | 2009-07-07 | 2011-01-13 | Robert Shorr | Pharmaceutical composition |
SI2462246T1 (en) * | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
DK3403654T3 (en) | 2009-10-01 | 2019-08-26 | Adare Dev I L P | ORAL ADMINISTRATED CORTIC COSTEROIDS COMPOSITIONS |
EP2488018B1 (en) * | 2009-10-16 | 2019-05-22 | Copperhead Chemical Company | Methods and compositions for novel liquid crystal delivery systems |
WO2011050457A1 (en) | 2009-10-26 | 2011-05-05 | The University Of British Columbia | Stabilized formulation for oral administration of therapeutic agents and related methods |
US8853269B2 (en) * | 2010-02-04 | 2014-10-07 | Copperhead Chemical Company Inc. | Composition and method for treating infections and promoting intestinal health |
EP2547206B1 (en) | 2010-03-15 | 2016-05-11 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
WO2011138802A1 (en) * | 2010-05-07 | 2011-11-10 | Sun Pharma Advanced Research Company Ltd., | Injection solution |
WO2012039768A2 (en) * | 2010-09-24 | 2012-03-29 | Texas Southern University | Itraconazole formulations |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012144943A1 (en) * | 2011-04-18 | 2012-10-26 | Lipidor Ab | Liquid carrier for oral delivery of a pharmacologically active agent |
CN103596542A (en) * | 2011-04-27 | 2014-02-19 | Isp投资公司 | Clear wet sprays and gels |
SE1300709A1 (en) * | 2013-11-14 | 2015-05-15 | Lipidor Ab | Composition and method of topical treatment |
DE102011103948A1 (en) * | 2011-06-06 | 2012-12-06 | B. Braun Melsungen Ag | Biopassivating coating of vascular prostheses with phospholipids containing nitrocarboxylic acids |
US8987199B2 (en) | 2011-06-15 | 2015-03-24 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
KR101494594B1 (en) * | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same |
EP2810657B1 (en) * | 2012-01-31 | 2016-09-21 | Santen Pharmaceutical Co., Ltd | Non-aqueous liquid composition |
WO2013162771A1 (en) * | 2012-04-23 | 2013-10-31 | Massachusetts Institute Of Technology | Lectin conjugates for mucin hydration |
US8822423B2 (en) * | 2012-05-17 | 2014-09-02 | Janssen Biotech, Inc. | Affinity peptides toward infliximab |
SG11201407678YA (en) | 2012-05-25 | 2014-12-30 | Camurus Ab | Somatostatin receptor agonist formulations |
CA2879942C (en) * | 2012-07-26 | 2020-06-02 | Camurus Ab | Opioid formulations |
IL296882A (en) * | 2012-07-26 | 2022-12-01 | Camurus Ab | Opioid formulations |
KR101586790B1 (en) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same |
KR101586789B1 (en) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same |
KR101586791B1 (en) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same |
WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MX2017005692A (en) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Powder formulation. |
BR102015027955B1 (en) | 2014-11-11 | 2021-03-09 | Colgate-Palmolive Company | method of making a composition for oral hygiene |
US9675667B2 (en) | 2015-02-10 | 2017-06-13 | Massachusetts Institute Of Technology | Isolated mucins and different microorganisms, and methods of use |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
EP3352735B1 (en) | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
WO2017100580A1 (en) * | 2015-12-10 | 2017-06-15 | Aaron Seitz | Sphingolipid coatings and process for manufacturing sphingolipid coatings effective for inhibiting biofilm formation |
CN105483076B (en) | 2015-12-23 | 2019-01-25 | 中国科学院生物物理研究所 | A kind of preparation method and applications of fat-body |
WO2017119928A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
US10335405B1 (en) * | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
TWI777515B (en) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | Methods of treating eosinophilic esophagitis |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
CN116650678A (en) | 2017-07-07 | 2023-08-29 | 德雷克塞尔大学 | Voltage activated therapeutic, diagnostic and/or diagnostic constructs |
CN111195348A (en) * | 2018-11-19 | 2020-05-26 | 南京济群医药科技股份有限公司 | Somatostatin nanosuspension and preparation method thereof |
BR112022025817A2 (en) | 2020-06-30 | 2023-01-10 | Chong Kun Dang Pharmaceutical Corp | INJECTABLE COMPOSITION COMPRISING GNRH ANALOG |
RU2746320C1 (en) * | 2020-07-27 | 2021-04-12 | Сергей Николаевич Таргонский | Method for producing lipid mixture and liposomal oral antiviral therapeutic and prophylactic agent using said lipid mixture |
EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278151A (en) * | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
US5660858A (en) * | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
Family Cites Families (517)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR640907A (en) | 1927-06-25 | 1928-07-24 | Automatic flow limiter | |
US2168437A (en) | 1935-04-10 | 1939-08-08 | Kenneth O Buercklin | Injection device |
US2110208A (en) | 1937-02-12 | 1938-03-08 | U S Standard Products Company | Antigen preparations |
US3025991A (en) | 1960-05-23 | 1962-03-20 | Carron Products Co | Bottle stopper |
GB1049104A (en) | 1963-05-11 | 1966-11-23 | Prodotti Antibiotici Spa | Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics |
US3122162A (en) | 1963-06-20 | 1964-02-25 | Asa D Sands | Flow control device |
US3632768A (en) | 1969-10-02 | 1972-01-04 | Upjohn Co | Therapeutic composition and method for treating infections with actinospectacin |
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4034756A (en) | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US3732865A (en) | 1971-01-13 | 1973-05-15 | Alza Corp | Osmotic dispenser |
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
BE795516A (en) | 1972-02-17 | 1973-08-16 | Ciba Geigy | PREPARATIONS OF OILY AND INJECTABLE PEPTIDES AND PROCESS FOR THEIR PREPARATION |
US3797492A (en) | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US3995632A (en) | 1973-05-04 | 1976-12-07 | Alza Corporation | Osmotic dispenser |
DE2528516A1 (en) | 1974-07-05 | 1976-01-22 | Sandoz Ag | NEW GALENIC PREPARATION |
US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4078060A (en) | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4111201A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4243030A (en) | 1978-08-18 | 1981-01-06 | Massachusetts Institute Of Technology | Implantable programmed microinfusion apparatus |
US4305927A (en) | 1979-02-05 | 1981-12-15 | Alza Corporation | Method for the management of intraocular pressure |
US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
US4310516A (en) | 1980-02-01 | 1982-01-12 | Block Drug Company Inc. | Cosmetic and pharmaceutical vehicle thickened with solid emulsifier |
AU546785B2 (en) | 1980-07-23 | 1985-09-19 | Commonwealth Of Australia, The | Open-loop controlled infusion of diabetics |
US4350271A (en) | 1980-08-22 | 1982-09-21 | Alza Corporation | Water absorbing fluid dispenser |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
US4340054A (en) | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
US4455145A (en) | 1981-07-10 | 1984-06-19 | Alza Corporation | Dispensing device with internal drive |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
EP0079143A3 (en) | 1981-10-20 | 1984-11-21 | Adnovum Ag | Pseudoplastic gel transfer |
EP0080879B1 (en) | 1981-11-28 | 1986-10-01 | Sunstar Kabushiki Kaisha | Pharmaceutical composition containing interferon in stable state |
US5004689A (en) | 1982-02-22 | 1991-04-02 | Biogen, Massachusetts | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4455143A (en) | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4753651A (en) | 1982-08-30 | 1988-06-28 | Alza Corporation | Self-driven pump |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4552561A (en) | 1982-12-23 | 1985-11-12 | Alza Corporation | Body mounted pump housing and pump assembly employing the same |
US4673405A (en) | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
DE3320583A1 (en) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF |
JPS6058915A (en) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | Lipid microcapsule preparation containing medicament |
US4594108A (en) | 1983-09-19 | 1986-06-10 | The Dow Chemical Company | Highly pseudoplastic polymer solutions |
US5385738A (en) | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
MX9203641A (en) | 1983-12-16 | 1992-07-01 | Genentech Inc | RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING. |
US4851228A (en) | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
US5120832A (en) | 1984-08-27 | 1992-06-09 | Genentech, Inc. | Distinct family of human leukocyte interferons |
US4927687A (en) | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
FI90990C (en) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Recombinant DNA molecule, transformed host organism, and method for producing interferon |
US4655462A (en) | 1985-01-07 | 1987-04-07 | Peter J. Balsells | Canted coiled spring and seal |
JPS61189230A (en) | 1985-02-19 | 1986-08-22 | Nippon Kayaku Co Ltd | Etoposide preparation |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
US4845196A (en) | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
DE3607835A1 (en) | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | HYBRID INTERFERONS, THEIR USE AS MEDICINAL PRODUCTS AND AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIBODIES AND THE USE THEREOF AND METHOD FOR THEIR PRODUCTION |
US4865845A (en) | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
DE3636123A1 (en) | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
DE3642096A1 (en) | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | HORSE (GAMMA) INTERFERON |
US5371089A (en) | 1987-02-26 | 1994-12-06 | Senetek, Plc | Method and composition for ameliorating the adverse effects of aging |
JPH0720866B2 (en) | 1987-05-15 | 1995-03-08 | 三生製薬株式会社 | Transdermal preparation containing eperisone or tolperisone or their salts |
US4940465A (en) | 1987-05-27 | 1990-07-10 | Felix Theeuwes | Dispenser comprising displaceable matrix with solid state properties |
US4892778A (en) | 1987-05-27 | 1990-01-09 | Alza Corporation | Juxtaposed laminated arrangement |
US5938654A (en) | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5023088A (en) | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
US4874388A (en) | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
US4915949A (en) | 1987-07-13 | 1990-04-10 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4886668A (en) | 1987-09-24 | 1989-12-12 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic pump |
US4917895A (en) | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
US5160122A (en) | 1990-03-20 | 1992-11-03 | Peter J. Balsells | Coil spring with an elastomer having a hollow coil cross section |
US4964204A (en) | 1988-04-25 | 1990-10-23 | Peter J. Balsells | Method for making a garter-type axially-resilient coil spring |
US4915366A (en) | 1988-04-25 | 1990-04-10 | Peter J. Balsells | Outside back angle canted coil spring |
US4974821A (en) | 1988-04-25 | 1990-12-04 | Peter J. Balsells | Canted-coil spring with major axis radial loading |
US5072070A (en) | 1989-12-01 | 1991-12-10 | Peter J. Balsells | Device for sealing electromagnetic waves |
US4826144A (en) | 1988-04-25 | 1989-05-02 | Peter J. Balsells | Inside back angle canted coil spring |
DE68909295T2 (en) | 1988-04-25 | 1994-05-11 | Peter J Balsells | Self-contained ring-shaped coil spring with an external, rearward angle of inclination. |
US4961253A (en) | 1988-04-25 | 1990-10-09 | Peter J. Balsells | Manufacturing method for canted-coil spring with turn angle and seal |
US4830344A (en) | 1988-04-25 | 1989-05-16 | Peter J. Balsells | Canted-coil spring with turn angle and seal |
US5108078A (en) | 1988-04-25 | 1992-04-28 | Peter J. Balsells | Canted-coil spring loaded while in a cavity |
US4893795A (en) | 1988-08-15 | 1990-01-16 | Peter J. Balsells | Radially loaded canted coiled spring with turn angle |
US5079388A (en) | 1989-12-01 | 1992-01-07 | Peter J. Balsells | Gasket for sealing electromagnetic waves |
US5117066A (en) | 1988-04-25 | 1992-05-26 | Peter J. Balsells | Retaining and locking electromagnetic gasket |
US4907788A (en) | 1988-04-25 | 1990-03-13 | Peter J. Balsells | Dual concentric canted-coil spring apparatus |
US4876781A (en) | 1988-04-25 | 1989-10-31 | Peter J. Balsells | Method of making a garter-type axially resilient coiled spring |
US5203849A (en) | 1990-03-20 | 1993-04-20 | Balsells Peter J | Canted coil spring in length filled with an elastomer |
US4934666A (en) | 1988-04-25 | 1990-06-19 | Peter J. Balsells | Coiled spring electromagnetic shielding gasket |
US5024842A (en) | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5160743A (en) | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US4931285A (en) | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
JP2794022B2 (en) | 1988-11-11 | 1998-09-03 | 三生製薬株式会社 | Transdermal preparation containing bunazosin or its salts |
US5728088A (en) | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5057318A (en) | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5059423A (en) | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5110596A (en) | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5234424A (en) | 1988-12-28 | 1993-08-10 | Alza Corporation | Osmotically driven syringe |
US4969884A (en) | 1988-12-28 | 1990-11-13 | Alza Corporation | Osmotically driven syringe |
US4976966A (en) | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
US5288479A (en) | 1989-01-17 | 1994-02-22 | Sterling Drug, Inc. | Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof |
US5906816A (en) | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5219572A (en) | 1989-03-17 | 1993-06-15 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5126142A (en) | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5112614A (en) | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
SE465950B (en) | 1989-10-23 | 1991-11-25 | Medinvent Sa | Combination of an aggregate particle size, crystalline or freeze-dried drug with a pseudoplastic gel for preparation of an injectable preparation as well as a process for its preparation |
US5358501A (en) | 1989-11-13 | 1994-10-25 | Becton Dickinson France S.A. | Storage bottle containing a constituent of a medicinal solution |
JPH03236317A (en) | 1989-12-06 | 1991-10-22 | Sansei Seiyaku Kk | Dopamine derivative-containing percutaneous |
US5030216A (en) | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5213809A (en) | 1990-01-24 | 1993-05-25 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5122128A (en) | 1990-03-15 | 1992-06-16 | Alza Corporation | Orifice insert for a ruminal bolus |
US5120306A (en) | 1990-03-21 | 1992-06-09 | Gosselin Leon F | Direct delivery of anti-inflammatories to the proximal small bowel |
US5207752A (en) | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5290271A (en) | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5374620A (en) | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
US5180591A (en) | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234693A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234695A (en) | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
US5300302A (en) | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
US5151093A (en) | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
IT1243390B (en) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION. |
US5161806A (en) | 1990-12-17 | 1992-11-10 | Peter J. Balsells | Spring-loaded, hollow, elliptical ring seal |
GB9027422D0 (en) | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
MX9200038A (en) | 1991-01-09 | 1992-11-01 | Alza Corp | BIODEGRADABLE DEVICES AND COMPOSITIONS FOR THE RELEASE BY DIFFUSION OF AGENTS. |
US5443459A (en) | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5861166A (en) | 1991-03-12 | 1999-01-19 | Alza Corporation | Delivery device providing beneficial agent stability |
US5113938A (en) | 1991-05-07 | 1992-05-19 | Clayton Charley H | Whipstock |
US5137727A (en) | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
EP0520119A1 (en) | 1991-06-17 | 1992-12-30 | Spirig Ag Pharmazeutische Präparate | New oral diclofenac composition |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
US5288214A (en) | 1991-09-30 | 1994-02-22 | Toshio Fukuda | Micropump |
YU87892A (en) | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE |
DE69229881T2 (en) | 1991-10-04 | 1999-12-09 | Yoshitomi Pharmaceutical | DELAYED RELEASE TABLET |
AU2867492A (en) | 1991-10-10 | 1993-05-03 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
DE4137649C2 (en) | 1991-11-15 | 1997-11-20 | Gerhard Dingler | Component |
WO1993009763A1 (en) | 1991-11-15 | 1993-05-27 | Isp Investments Inc. | Pharmaceutical tablet with pvp having an enhanced drug dissolution rate |
US5200195A (en) | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5223265A (en) | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5209746A (en) | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5456679A (en) | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5221278A (en) | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
ZA932273B (en) | 1992-03-30 | 1993-11-26 | Alza Corp | Additives for bioerodible polymers to regulate degradation |
MX9301823A (en) | 1992-03-30 | 1994-01-31 | Alza Corp | COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT. |
US6197346B1 (en) | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
FR2690622B1 (en) | 1992-04-29 | 1995-01-20 | Chronotec | Programmable ambulatory infusion pump system. |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5413672A (en) | 1992-07-22 | 1995-05-09 | Ngk Insulators, Ltd. | Method of etching sendust and method of pattern-etching sendust and chromium films |
US5512293A (en) | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
GB9223146D0 (en) | 1992-11-05 | 1992-12-16 | Scherer Corp R P | Vented capsule |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
SE9203594D0 (en) | 1992-11-30 | 1992-11-30 | Christer Nystroem | DISPERSA SYSTEM MEDICINAL PRODUCT |
US5368588A (en) | 1993-02-26 | 1994-11-29 | Bettinger; David S. | Parenteral fluid medication reservoir pump |
AU6410494A (en) | 1993-03-17 | 1994-10-11 | Alza Corporation | Device for the transdermal administration of alprazolam |
US5514110A (en) | 1993-03-22 | 1996-05-07 | Teh; Eutiquio L. | Automatic flow control device |
NZ250844A (en) | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
NZ247516A (en) | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5639477A (en) | 1993-06-23 | 1997-06-17 | Alza Corporation | Ruminal drug delivery device |
ATE149349T1 (en) | 1993-06-25 | 1997-03-15 | Alza Corp | INCORPORATING A POLY-N-VINYLAMIDE INTO A TRANSDERMAL SYSTEM |
US5498255A (en) | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
JP2700141B2 (en) | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | Calcium hydrogen phosphate, its production method and excipient using the same |
CA2165802A1 (en) | 1993-09-29 | 1995-04-06 | Eun Soo Lee | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
US5540665A (en) | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
PL178438B1 (en) | 1994-02-04 | 2000-04-28 | Scotia Lipidteknik Ab | Lipid bistrate preparations |
US5697975A (en) | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
ATE227133T1 (en) | 1994-03-07 | 2002-11-15 | Imperial College | USE OF INTERFERON-ALPHA 8 SUBTYPE FOR PRODUCING MEDICATIONS FOR TREATING VIRAL INFECTIONS OF THE LIVER |
EP0768867B1 (en) | 1994-06-13 | 2002-10-09 | Alza Corporation | Dosage form for administering drug in liquid formulation |
NL9401150A (en) | 1994-07-12 | 1996-02-01 | Nederland Ptt | Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver. |
ATE197396T1 (en) | 1994-07-13 | 2000-11-11 | Alza Corp | COMPOSITION AND METHOD FOR PROMOTING TRANSDERMAL ELECTRICAL TRANSPORT DOSAGE |
US5633011A (en) | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5595759A (en) | 1994-11-10 | 1997-01-21 | Alza Corporation | Process for providing therapeutic composition |
AU708529B2 (en) | 1994-11-10 | 1999-08-05 | University Of Kentucky Research Foundation, The | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
FR2731150B1 (en) | 1995-03-03 | 1997-04-18 | Oreal | USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA |
US5844017A (en) | 1995-03-06 | 1998-12-01 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters containing amines and/or amido groups |
US5464929A (en) | 1995-03-06 | 1995-11-07 | Ethicon, Inc. | Absorbable polyoxaesters |
US5597579A (en) | 1995-03-06 | 1997-01-28 | Ethicon, Inc. | Blends of absorbable polyoxaamides |
US5607687A (en) | 1995-03-06 | 1997-03-04 | Ethicon, Inc. | Polymer blends containing absorbable polyoxaesters |
US5859150A (en) | 1995-03-06 | 1999-01-12 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters |
US6100346A (en) | 1995-03-06 | 2000-08-08 | Ethicon, Inc. | Copolymers of polyoxaamides |
US5700583A (en) | 1995-03-06 | 1997-12-23 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters containing amines or amido groups |
US5698213A (en) | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
US5962023A (en) | 1995-03-06 | 1999-10-05 | Ethicon, Inc. | Hydrogels containing absorbable polyoxaamides |
US5618552A (en) | 1995-03-06 | 1997-04-08 | Ethicon, Inc. | Absorbable polyoxaesters |
US5595751A (en) | 1995-03-06 | 1997-01-21 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/or amido groups |
US5648088A (en) | 1995-03-06 | 1997-07-15 | Ethicon, Inc. | Blends of absorbable polyoxaesters containing amines and/or amide groups |
US6403655B1 (en) | 1995-03-06 | 2002-06-11 | Ethicon, Inc. | Method of preventing adhesions with absorbable polyoxaesters |
US6147168A (en) | 1995-03-06 | 2000-11-14 | Ethicon, Inc. | Copolymers of absorbable polyoxaesters |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
WO1996034628A1 (en) | 1995-05-02 | 1996-11-07 | Taisho Pharmaceutical Co., Ltd. | Composition for oral administration |
US5939286A (en) | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
MX9709193A (en) | 1995-06-06 | 1998-03-31 | Hoffmann La Roche | Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride. |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
ES2190472T5 (en) | 1995-06-07 | 2012-03-09 | Ortho-Mcneil Pharmaceutical, Inc. | TRANSDERMAL PATCH FOR THE ADMINISTRATION OF 17-DEACETIL NORGESTIMATO, IN COMBINATION WITH A STROGEN. |
US5690952A (en) | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
US5782396A (en) | 1995-08-28 | 1998-07-21 | United States Surgical Corporation | Surgical stapler |
US5906830A (en) | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
GB9521125D0 (en) | 1995-10-16 | 1995-12-20 | Unilever Plc | Cosmetic composition |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
GB9521805D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Solubilisation methods |
ATE235505T1 (en) | 1995-10-30 | 2003-04-15 | Oleoyl Estrone Developments S | OLEAT MONOESTER OF ESTROGENS FOR THE TREATMENT OF OBESITY |
JP2000507917A (en) * | 1995-11-02 | 2000-06-27 | シェーリング コーポレイション | Continuous low-dose cytokine infusion therapy |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
AUPN723395A0 (en) * | 1995-12-19 | 1996-01-18 | Macnaught Medical Pty Limited | Lubrication methods |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
CA2279349C (en) | 1996-02-02 | 2007-09-25 | Rhomed Incorporated | Ascorbate-stabilized radiopharmaceutical method and composition |
ATE284202T1 (en) | 1996-02-02 | 2004-12-15 | Alza Corp | IMPLANTABLE DELAYED RELEASE SYSTEM |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
JPH09241153A (en) | 1996-03-04 | 1997-09-16 | Q P Corp | Lipid emulsion for intravenous injection |
US6124281A (en) | 1996-03-08 | 2000-09-26 | Zeneca Limited | Azolobenzazepine derivatives as neurologically active agents |
EP0904373A1 (en) | 1996-03-14 | 1999-03-31 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US5703200A (en) | 1996-03-15 | 1997-12-30 | Ethicon, Inc. | Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer |
US6204022B1 (en) | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
US6074673A (en) | 1996-04-22 | 2000-06-13 | Guillen; Manuel | Slow-release, self-absorbing, drug delivery system |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
US6214367B1 (en) | 1996-06-05 | 2001-04-10 | Ashmont Holdings Limited | Injectable compositions |
WO1997046584A1 (en) | 1996-06-05 | 1997-12-11 | Boehringer Mannheim Gmbh | Exendin analogues, processes for their preparation and medicaments containing them |
DE29610419U1 (en) | 1996-06-14 | 1996-10-24 | Filtertek Sa | Gravity infusion device for medical infusions |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
ATE241997T1 (en) | 1996-07-03 | 2003-06-15 | Alza Corp | NON-AQUEOUS PROTIC PEPTIDE PREPARATIONS |
US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
ES2227707T3 (en) | 1996-07-15 | 2005-04-01 | Alza Corporation | NEW FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FLUOXETINE ACETATE AND FLUOXETINE MALEATE. |
AR008789A1 (en) | 1996-07-31 | 2000-02-23 | Bayer Corp | PIRIDINES AND SUBSTITUTED BIPHENYLS |
US6956026B2 (en) | 1997-01-07 | 2005-10-18 | Amylin Pharmaceuticals, Inc. | Use of exendins for the reduction of food intake |
JP2001501593A (en) | 1996-08-08 | 2001-02-06 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Methods for regulating gastrointestinal motility |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
IN184589B (en) | 1996-10-16 | 2000-09-09 | Alza Corp | |
AU4990797A (en) | 1996-10-24 | 1998-05-15 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
US5817129A (en) | 1996-10-31 | 1998-10-06 | Ethicon, Inc. | Process and apparatus for coating surgical sutures |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
DE19646392A1 (en) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US5928666A (en) | 1996-11-12 | 1999-07-27 | Cygnus Inc. | Crystalline form of estradiol and pharmaceutical formulations comprising same |
AU5175998A (en) | 1996-11-15 | 1998-06-03 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
DE69705746T2 (en) | 1996-12-20 | 2001-10-31 | Alza Corp | INJECTABLE DEPOT GEL PREPARATION AND PRODUCTION METHOD |
GB9626513D0 (en) | 1996-12-20 | 1997-02-05 | Bioglan Ireland R & D Ltd | A pharmaceutical composition |
JP2001511128A (en) | 1997-01-28 | 2001-08-07 | ファルマシア・アンド・アップジョン・カンパニー | Lyophilized product of lipid complex of water-insoluble porphyrin |
ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
US5874388A (en) | 1997-04-02 | 1999-02-23 | Dow Corning Corporation | Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant |
US6127520A (en) | 1997-04-15 | 2000-10-03 | Regents Of The University Of Michigan | Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles |
JP2001524958A (en) | 1997-04-17 | 2001-12-04 | ジーエス ディベロップメント アクティエボラーグ | A novel liquid crystal based bioadhesive drug delivery system |
CN1177934C (en) | 1997-04-28 | 2004-12-01 | 阿文蒂斯药物股份有限公司 | Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6663899B2 (en) * | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
SI9700186B (en) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical preparation with controlled release of active healing substances |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
MY125870A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
JPH11100353A (en) | 1997-09-29 | 1999-04-13 | Esupo Kk | Refined and deodorized liquid ester wax and its composition |
JP2001517692A (en) | 1997-09-29 | 2001-10-09 | インヘール セラピューティック システムズ, インコーポレイテッド | Stabilized preparation for use in a nebulizer |
US6133429A (en) | 1997-10-03 | 2000-10-17 | Becton Dickinson And Company | Chromophores useful for the preparation of novel tandem conjugates |
DK1032587T4 (en) | 1997-11-14 | 2013-04-08 | Amylin Pharmaceuticals Llc | New exendin agonist compounds |
JP2001526033A (en) | 1997-12-08 | 2001-12-18 | ジェネンテク・インコーポレイテッド | Human interferon-type I interferon called epsilon |
US6368612B1 (en) | 1997-12-12 | 2002-04-09 | Biohybrid Technologies Llc | Devices for cloaking transplanted cells |
EP1041975B1 (en) | 1997-12-22 | 2002-09-04 | Alza Corporation | Rate controlling membranes for controlled drug delivery devices |
AU1828599A (en) | 1997-12-29 | 1999-07-19 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
PT1044032E (en) | 1997-12-29 | 2004-08-31 | Alza Corp | IMPLANTING DEVICE FOR SEBCUTANEOUS IMPLANTS |
AR013256A1 (en) | 1997-12-30 | 2000-12-13 | Intarcia Therapeutics Inc | ADMINISTRATION ARRANGEMENT FOR A CONTROLLED ADMINISTRATION OF A CHARITY AGENT, METHOD FOR FORMING AN ADMINISTRATION ARRANGEMENT, METHOD FOR MAKING AN ADMINISTRATION ARRANGEMENT AND METHOD OF CONTROLLING A SPEED OF FREEDOM. |
ATE248002T1 (en) * | 1997-12-31 | 2003-09-15 | Alza Corp | SYSTEM FOR MONITORING AN OSMOTIC DRUG DELIVERY DEVICE |
US20040024068A1 (en) | 1998-01-23 | 2004-02-05 | Trustees Of Tufts College | Antimicrobial compounds |
IT1298575B1 (en) | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF |
US6017545A (en) | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
ATE366115T1 (en) | 1998-02-13 | 2007-07-15 | Amylin Pharmaceuticals Inc | INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1 |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US6224577B1 (en) | 1998-03-02 | 2001-05-01 | Medrad, Inc. | Syringes and plungers for use therein |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
WO1999046332A1 (en) | 1998-03-12 | 1999-09-16 | Daicel Chemical Industries, Ltd. | Lactone-containing resin composition, molded object thereof, and film |
US6029361A (en) | 1998-03-25 | 2000-02-29 | Ultratech Stepper, Inc. | Air-guage nozzle probe structure for microlithographic image focusing |
US6074660A (en) | 1998-04-20 | 2000-06-13 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/ or amido groups |
TW586944B (en) | 1998-05-29 | 2004-05-11 | Sumitomo Pharma | Controlled release agent having a multi-layer structure |
AU758825B2 (en) | 1998-06-12 | 2003-04-03 | Amylin Pharmaceuticals, Inc. | Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance |
US6472512B1 (en) | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US7390637B2 (en) | 1998-07-21 | 2008-06-24 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US6551613B1 (en) | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
KR100620292B1 (en) | 1998-09-09 | 2006-09-13 | 알자 코포레이션 | Dosage form comprising liquid formulation |
US6248112B1 (en) | 1998-09-30 | 2001-06-19 | C. R. Bard, Inc. | Implant delivery system |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
RU2246295C2 (en) | 1998-11-02 | 2005-02-20 | Элзэ Копэрейшн | Medicinal formulation with constant rate for releasing medicinal substance, core of medicinal formulation and method for providing relieved release of medicinal substance from medicinal formulation |
WO2000029206A1 (en) | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
BR9915961A (en) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Glp-1 analogs |
ATE260642T1 (en) | 1998-12-17 | 2004-03-15 | Alza Corp | CONVERSION OF LIQUID-FILLED GELATIN CAPSULES INTO SYSTEMS WITH CONTROLLED ACTIVE RELEASE THROUGH MULTIPLE COATINGS |
CN1158068C (en) | 1998-12-23 | 2004-07-21 | 安姆根有限公司 | Polyol/oil suspensions for the sustained release of proteins |
EP1140144A4 (en) | 1998-12-31 | 2002-10-30 | Viragen Inc | Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods |
ATE234603T1 (en) | 1998-12-31 | 2003-04-15 | Alza Corp | OSMOTIC ADMINISTRATION SYSTEM WITH SPACE-SAVING PISTONS |
US6433144B1 (en) * | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
WO2000040273A2 (en) | 1999-01-08 | 2000-07-13 | Vical Incorporated | Treatment of viral diseases using an interferon omega expressing polynucleotide |
US6703225B1 (en) | 1999-01-12 | 2004-03-09 | Sumitomo Pharmaceuticals Company, Limited | Interferon-α |
US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
JP4426727B2 (en) | 1999-01-14 | 2010-03-03 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Novel exendin agonist preparation and administration method thereof |
PT1143989E (en) | 1999-01-14 | 2007-03-30 | Amylin Pharmaceuticals Inc | Exendins for glucagon suppression |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
CN1232244C (en) | 1999-02-08 | 2005-12-21 | 阿尔萨公司 | Stable non-aqueous single phase viscons vehicles and formulations utilizing such vehicles |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US6835194B2 (en) | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6541021B1 (en) | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
CA2306039A1 (en) | 1999-04-19 | 2000-10-19 | Schering Corporation | Hcv combination therapy |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
WO2000067728A2 (en) | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
ATE252601T1 (en) | 1999-05-17 | 2003-11-15 | Conjuchem Inc | LONG-ACTING INSULINOTROPE PEPTIDES |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US20030059376A1 (en) | 1999-06-04 | 2003-03-27 | Libbey Miles A. | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
RU2271196C2 (en) | 1999-06-04 | 2006-03-10 | Элзэ Копэрейшн | Implantable composition (variants) and method for production thereof |
JP2003501404A (en) | 1999-06-04 | 2003-01-14 | デルルックス ファーマシューティカル コーポレイション | Preparation comprising dehydrated particles of drug and method of preparing same |
US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
WO2001043528A2 (en) | 1999-12-17 | 2001-06-21 | Durect Corporation | Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide |
ES2248156T3 (en) | 1999-12-21 | 2006-03-16 | Alza Corporation | VALVE FOR OSMOTIC DEVICES. |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
US6572890B2 (en) | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US6472060B1 (en) | 2000-01-19 | 2002-10-29 | Seco Tools Ab | Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction |
US6844321B2 (en) | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6471688B1 (en) | 2000-02-15 | 2002-10-29 | Microsolutions, Inc. | Osmotic pump drug delivery systems and methods |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
MXPA02009031A (en) | 2000-03-14 | 2004-08-19 | Amylin Pharmaceuticals Inc | Effects of glucagon like peptide 1 (7 36) on antro pyloro duodenal motility. |
US20030211974A1 (en) * | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
JP4361710B2 (en) | 2000-04-19 | 2009-11-11 | ジェネンテック・インコーポレーテッド | Sustained release formulation |
EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
JP2001357075A (en) | 2000-04-27 | 2001-12-26 | El-Con System Co Ltd | System and method for calculating quantity of materials while utilizing two-dimensional cad interface |
AU6323001A (en) | 2000-05-19 | 2001-12-03 | Bionebraska Inc | Treatment of acute coronary syndrome with glp-1 |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
DE60124710T2 (en) | 2000-06-16 | 2007-09-13 | Eli Lilly And Co., Indianapolis | ANALOG OF GLUCAGON SIMILAR PEPTIDE-1 |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
WO2002028366A2 (en) | 2000-10-06 | 2002-04-11 | Durect Corporation | Devices and methods for management of inflammation |
AU2002225870B2 (en) | 2000-11-03 | 2006-09-21 | Intarcia Therapeutics, Inc. | Method for short-term and long-term drug dosimetry |
CA2429898C (en) | 2000-11-16 | 2011-02-22 | Durect Corporation | Devices and methods for cholesterol management |
CA2429945A1 (en) | 2000-11-29 | 2002-06-06 | Durect Corporation | Devices and methods for controlled delivery from a drug delivery device |
US20020165286A1 (en) | 2000-12-08 | 2002-11-07 | Hanne Hedeman | Dermal anti-inflammatory composition |
MXPA03005135A (en) | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Chronic treatment regimen using glucagon-like insulinotropic peptides. |
US7199217B2 (en) | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
BR0116206A (en) | 2000-12-14 | 2003-12-23 | Amylin Pharmaceuticals Inc | Yy Peptide and yy Peptide Agonists for Treatment of Metabolic Disorders |
IN188924B (en) | 2001-03-01 | 2002-11-23 | Bharat Serums & Vaccines Ltd | |
WO2002076344A1 (en) | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
JP2005506956A (en) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | Long-acting GLP-1 formulation |
US6514517B2 (en) | 2001-06-20 | 2003-02-04 | Ethicon, Inc. | Antimicrobial coatings for medical devices |
AU2002320122B2 (en) | 2001-06-21 | 2007-07-26 | Genentech, Inc. | Sustained release formulation |
US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
AU2002304387A1 (en) | 2001-06-22 | 2003-01-08 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
CN1549724A (en) | 2001-07-20 | 2004-11-24 | ����ͨѶ�ɷ�����˾ | Methods of treating liver fibrosis |
JP2005501058A (en) | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | GLP-1, EXENDIN-4, peptide analogue thereof and use thereof |
BR0212080A (en) | 2001-08-23 | 2006-04-04 | Lilly Co Eli | glp-1 compound, method of glp-1 receptor stimulation in an individual in need of such stimulation, and use of a glp-1 compound |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
CN1585627A (en) | 2001-09-14 | 2005-02-23 | 弗朗西斯J·马丁 | Microfabricated nanopore device for sustained release of therapeutic agent |
EP1435919B1 (en) | 2001-09-17 | 2009-09-23 | Durect Corporation | Device and method for accurate delivery of an active agent |
EP2050460A1 (en) | 2001-09-24 | 2009-04-22 | Imperial Innovations Limited | PYY and agonists thereof for modification of feeding behaviour |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
MXPA04003238A (en) | 2001-10-05 | 2004-07-08 | Intermune Inc | Method of treating hepatitis virus infection with a multiphasic interferon delivery profile. |
US20040142902A1 (en) | 2001-11-08 | 2004-07-22 | Struijker- Boudier Harry A.J. | Implant dosage form and use thereof for the delivery of a cholosterol lowering agent |
NZ532779A (en) | 2001-11-09 | 2008-04-30 | Intarcia Therapeutics Inc | Method for treating diseases with omega interferon |
BR0206469A (en) | 2001-11-14 | 2004-01-13 | Alza Corp | Injectable Depot Composition |
US20030170289A1 (en) | 2001-11-14 | 2003-09-11 | Guohua Chen | Injectable depot compositions and uses thereof |
KR20040058101A (en) | 2001-11-14 | 2004-07-03 | 알자 코포레이션 | Catheter injectable depot compositions and uses thereof |
DE10159217A1 (en) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations |
US20030108608A1 (en) | 2001-12-12 | 2003-06-12 | Erik Laridon | Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver |
JP2005513095A (en) | 2001-12-19 | 2005-05-12 | アルザ・コーポレーシヨン | Formulations & dosage forms for controlled delivery of therapeutic agents |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
GB0204722D0 (en) | 2002-02-28 | 2002-04-17 | Norferm Da | Method |
GB2386066A (en) | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species |
KR20100112206A (en) | 2002-04-11 | 2010-10-18 | 메디뮨 엘엘씨 | Preservation of bioactive materials by spray drying |
JP2005533782A (en) | 2002-06-17 | 2005-11-10 | アルザ コーポレイション | An osmotic delivery system having an engine with fast extruding force and zero order including an osmotic agent dispersed in a fluid vehicle |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
AU2003256308B2 (en) | 2002-06-26 | 2008-07-03 | Intarcia Therapeutics, Inc. | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
US7177526B2 (en) | 2002-06-28 | 2007-02-13 | Intel Corporation | System and method for improving audio during post-production of video recordings |
MXPA05001242A (en) | 2002-07-31 | 2005-06-08 | Alza Corp | Injectable depot compositions and uses thereof. |
ES2321505T3 (en) | 2002-07-31 | 2009-06-08 | Alza Corporation | COMPOSITIONS OF MULTIMODAL POLYMER DEPOSIT INJECTABLE AND USE OF THE SAME. |
US20080260838A1 (en) | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
AU2003283004A1 (en) | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
BR0315304A (en) | 2002-11-06 | 2005-08-16 | Alza Corp | Depot formulations for controlled release |
US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
JP2006512370A (en) | 2002-12-19 | 2006-04-13 | アルザ・コーポレーション | A stable non-aqueous single phase gel and its formulation for delivery from an implantable device |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
JP2004238392A (en) | 2003-01-14 | 2004-08-26 | Nipro Corp | Stabilized proteinic preparation |
JP2006518093A (en) | 2003-02-18 | 2006-08-03 | メドコンクス, インコーポレイテッド | Application for Friction-Fitting Designed Male Medical Device Electrical Connector This application is filed on February 18, 2003, “A Method for Fitting and Locking an Annular Male Connector that Can Create a Universal Connector System” Claims the benefit of priority under Section 119 of the United States Patents Act of US Provisional Patent Application No. 60 / 448,517. |
KR20050120767A (en) | 2003-03-31 | 2005-12-23 | 알자 코포레이션 | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
RU2005133427A (en) | 2003-03-31 | 2006-04-27 | Алза Корпорейшн (Us) | WATERLESS SINGLE-PHASE CARRIERS AND DRUGS USING SUCH CARRIERS |
AR043809A1 (en) | 2003-03-31 | 2005-08-17 | Alza Corp | OSMOTIC PUMP WITH MEDIUM TO DISSIP INTERNAL PRESSURE |
KR20060003100A (en) | 2003-05-16 | 2006-01-09 | 블루 멤브레인스 게엠베하 | Medical implants comprising biocompatible coatings |
US8008255B2 (en) | 2003-05-30 | 2011-08-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for enhanced transmucosal delivery of peptides and proteins |
AU2004245022A1 (en) | 2003-05-30 | 2004-12-16 | Alza Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
CN102940879B (en) | 2003-06-03 | 2017-06-06 | 诺沃挪第克公司 | Stabilized pharmaceutical peptide compositions |
US8491571B2 (en) | 2003-06-12 | 2013-07-23 | Cordis Corporation | Orifice device having multiple channels with varying flow rates for drug delivery |
US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
CN1859900A (en) * | 2003-09-30 | 2006-11-08 | 阿尔萨公司 | Osmotically driven active agent delivery device providing an ascending release profile |
US7407499B2 (en) | 2003-10-31 | 2008-08-05 | Intarcia Therapeutics, Inc. | Osmotic pump with self-retaining, fast-start membrane plug |
MXPA06003065A (en) | 2003-11-06 | 2006-05-31 | Alza Corp | Modular imbibition rate reducer for use with implantable osmotic pump. |
US20050106214A1 (en) | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
US20050118206A1 (en) | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US20050281879A1 (en) | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
US7780973B2 (en) | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
WO2005077072A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
CN1968700A (en) | 2004-04-15 | 2007-05-23 | 阿尔克姆斯有限公司 | Polymer-based sustained release device |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
WO2006000567A2 (en) | 2004-06-28 | 2006-01-05 | Novo Nordisk A/S | Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function |
US7772182B2 (en) | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
JP5244388B2 (en) | 2004-08-18 | 2013-07-24 | ウオーターズ・テクノロジーズ・コーポレイシヨン | Apparatus and method for generating or carrying fluid under pressure and seal member used in the apparatus |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
EP2286838A3 (en) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related disorders |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
EP1841448A2 (en) | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring beta-cell mass and function |
CA2595457A1 (en) | 2005-01-25 | 2006-08-03 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
US20060216242A1 (en) | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
WO2006084141A2 (en) | 2005-02-03 | 2006-08-10 | Intarcia Therapeutics, Inc | Suspension formulation of interferon |
US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
EP2390264A1 (en) | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
ATE480255T1 (en) | 2005-03-31 | 2010-09-15 | Amylin Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR CONTROL, PREVENTION AND TREATMENT OF EATING DISORDERS |
ATE509634T1 (en) | 2005-04-08 | 2011-06-15 | Amylin Pharmaceuticals Inc | PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT |
EP1874339A1 (en) | 2005-04-21 | 2008-01-09 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
US7641649B2 (en) | 2005-05-06 | 2010-01-05 | Medtronic Minimed, Inc. | Reservoir support and method for infusion device |
US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
WO2007013957A2 (en) | 2005-07-22 | 2007-02-01 | University Of Utah Research Foundation | Osmotically driven dispense pump and related components for use in high pressure applications |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
EP2347762B1 (en) | 2005-08-19 | 2019-05-08 | Amylin Pharmaceuticals, LLC | Exendin for treating diabetes and reducing body weight |
ES2586236T3 (en) | 2005-11-04 | 2016-10-13 | Glaxosmithkline Llc | Procedures for administering hypoglycemic agents |
WO2007075439A2 (en) | 2005-12-16 | 2007-07-05 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating obesity and related metabolic disorders |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
RU2427383C2 (en) | 2006-01-18 | 2011-08-27 | КьюПиЭс, ЭлЭлСи | High stability pharmaceutical compositions |
AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
JP2009535380A (en) | 2006-05-02 | 2009-10-01 | アクトジェニックス・エヌブイ | Microbial intestinal delivery of obesity-related peptides |
EP2029160A2 (en) | 2006-05-12 | 2009-03-04 | Amylin Pharmaceuticals, Inc. | Methods to restore glycemic control |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
KR20140109509A (en) | 2006-07-11 | 2014-09-15 | 큐피에스 엘엘씨 | Pharmaceutical compositions for sustained release delivery of peptides |
WO2008019147A2 (en) | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
WO2008061355A1 (en) | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US20090022727A1 (en) | 2007-01-26 | 2009-01-22 | Alza Corp. | Injectable, nonaqueous suspension with high concentration of therapeutic agent |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8236760B2 (en) | 2007-04-27 | 2012-08-07 | Cedars-Sinsai Medical Center | Use of GLP-1 receptor agonists for the treatment of short bowel syndrome |
JP5718058B2 (en) | 2008-02-08 | 2015-05-13 | キューピーエス リミテッド ライアビリティ カンパニー | Composition for slow broadcast of protein or peptide |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
EP2254659B1 (en) | 2008-02-14 | 2017-06-14 | Enteromedics Inc. | Treatment of excess weight by neural downregulation in combination with compositions |
US20110046071A1 (en) | 2008-03-05 | 2011-02-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer |
CA2963659C (en) | 2008-09-17 | 2020-06-23 | Chiasma Inc. | Use of oral octreotride compositions |
KR101419583B1 (en) | 2008-10-15 | 2014-07-25 | 인타르시아 세라퓨틱스 인코포레이티드 | Highly concentrated drug particles, formulations, suspensions and uses thereof |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Oxyntomodulin peptide analogue |
AR079344A1 (en) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY |
WO2011156407A2 (en) | 2010-06-09 | 2011-12-15 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonists to treat pancre-atitis |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
-
2004
- 2004-11-15 US US10/988,716 patent/US7731947B2/en active Active
- 2004-11-16 AR ARP040104220A patent/AR046844A1/en unknown
- 2004-11-16 CA CA002546321A patent/CA2546321A1/en not_active Withdrawn
- 2004-11-16 BR BRPI0416613-2A patent/BRPI0416613A/en not_active IP Right Cessation
- 2004-11-16 MX MXPA06005565A patent/MXPA06005565A/en unknown
- 2004-11-16 JP JP2006541326A patent/JP4824574B2/en active Active
- 2004-11-16 KR KR1020067009498A patent/KR20060123160A/en not_active Application Discontinuation
- 2004-11-16 NZ NZ547079A patent/NZ547079A/en unknown
- 2004-11-16 TW TW093135004A patent/TW200534863A/en unknown
- 2004-11-16 EP EP04811199A patent/EP1689363A4/en not_active Withdrawn
- 2004-11-16 PE PE2004001125A patent/PE20050926A1/en not_active Application Discontinuation
- 2004-11-16 WO PCT/US2004/038409 patent/WO2005048952A2/en active Application Filing
- 2004-11-16 AU AU2004291162A patent/AU2004291162B2/en active Active
- 2004-11-16 EP EP09010536A patent/EP2116230A3/en not_active Withdrawn
-
2006
- 2006-05-11 IL IL175606A patent/IL175606A/en active IP Right Grant
- 2006-06-19 NO NO20062867A patent/NO20062867L/en not_active Application Discontinuation
-
2009
- 2009-12-29 US US12/655,397 patent/US7964183B2/en active Active
-
2011
- 2011-04-20 US US13/090,947 patent/US8257691B2/en active Active
- 2011-04-21 US US13/091,970 patent/US8398967B2/en active Active
-
2012
- 2012-08-29 US US13/598,405 patent/US9724293B2/en not_active Expired - Fee Related
-
2017
- 2017-07-25 US US15/658,965 patent/US20170319470A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278151A (en) * | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
US5660858A (en) * | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940316B2 (en) | 2005-02-03 | 2015-01-27 | Intarcia Therapeutics, Inc. | Osmotic delivery comprising an insulinotropic peptide and uses thereof |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Also Published As
Publication number | Publication date |
---|---|
US20110195097A1 (en) | 2011-08-11 |
AU2004291162A1 (en) | 2005-06-02 |
US8257691B2 (en) | 2012-09-04 |
PE20050926A1 (en) | 2005-11-08 |
EP2116230A3 (en) | 2010-09-29 |
KR20060123160A (en) | 2006-12-01 |
BRPI0416613A (en) | 2007-01-16 |
US20170319470A1 (en) | 2017-11-09 |
EP1689363A2 (en) | 2006-08-16 |
MXPA06005565A (en) | 2006-08-11 |
TW200534863A (en) | 2005-11-01 |
US7731947B2 (en) | 2010-06-08 |
US9724293B2 (en) | 2017-08-08 |
IL175606A (en) | 2014-04-30 |
JP2007527869A (en) | 2007-10-04 |
US8398967B2 (en) | 2013-03-19 |
AR046844A1 (en) | 2005-12-28 |
US7964183B2 (en) | 2011-06-21 |
JP4824574B2 (en) | 2011-11-30 |
NZ547079A (en) | 2009-03-31 |
AU2004291162B2 (en) | 2009-07-30 |
CA2546321A1 (en) | 2005-06-02 |
EP1689363A4 (en) | 2009-07-01 |
EP2116230A2 (en) | 2009-11-11 |
US20110208168A1 (en) | 2011-08-25 |
US20100112070A1 (en) | 2010-05-06 |
NO20062867L (en) | 2006-08-17 |
US20050112188A1 (en) | 2005-05-26 |
US20130052237A1 (en) | 2013-02-28 |
WO2005048952A2 (en) | 2005-06-02 |
IL175606A0 (en) | 2006-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005048952A3 (en) | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | |
WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
WO2003082247A3 (en) | Drug microparticles | |
WO2004093795A3 (en) | Compositions for delivery of drug combinations | |
EP1589947B8 (en) | Pharmaceutical formulation with an insoluble active agent for pulmonary administration | |
WO2006037116A3 (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
WO2005025499A3 (en) | Hydrophobic drug compositions containing reconstitution enhancer | |
WO2004039428A3 (en) | Transdermal delivery system for dried particulate or lyophilized medications | |
WO2005099676A3 (en) | Transdermal delivery system for use with basic permeation enhancers | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
WO2006101815A3 (en) | Pharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems | |
EP2106787A3 (en) | Biodegradable block copolymeric compositions for drug delivery | |
CA2326485A1 (en) | Anticancer compositions | |
BRPI0406911A (en) | Pharmaceutical and / or cosmetic product | |
WO2003000226A3 (en) | Pharmaceutical compositions containing polymer and drug assemblies | |
WO2005051456A3 (en) | Composition and apparatus for transdermal delivery | |
CA2535364A1 (en) | Hyaluronic acid nanoparticles | |
WO2002045683A3 (en) | Reversible gelling system for ocular drug delivery | |
WO2004087043A3 (en) | Stable ophthalmic formulation containing an antibiotic and a corticosteroid | |
EP2322146A3 (en) | Microcapsule formulations comprising two pharmaceutically active ingredients | |
WO2007056205A3 (en) | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents | |
WO2006138735A3 (en) | Gel compositions for topical administration | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
CA2516400A1 (en) | Intranasal formulation of rotigotine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480038511.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 547079 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 175606 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1279/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2546321 Country of ref document: CA Ref document number: 1020067009498 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006541326 Country of ref document: JP Ref document number: PA/a/2006/005565 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004291162 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004811199 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004291162 Country of ref document: AU Date of ref document: 20041116 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/04967 Country of ref document: ZA Ref document number: 200604967 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004291162 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004811199 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067009498 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0416613 Country of ref document: BR |